<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871282</url>
  </required_header>
  <id_info>
    <org_study_id>AL-DES-01</org_study_id>
    <nct_id>NCT04871282</nct_id>
  </id_info>
  <brief_title>A Study of AL102 in Patients With Progressing Desmoid Tumors</brief_title>
  <acronym>RINGSIDE</acronym>
  <official_title>RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayala Pharmaceuticals, Inc,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ayala Pharmaceuticals, Inc,</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to evaluate the efficacy and safety of AL102 in patients with&#xD;
      progressive desmoid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting&#xD;
      of 2 parts. Part A is an open-label, dose regimen finding study; Part B is a double blind,&#xD;
      placebo-controlled study utilizing the dose regimen selected in Part A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Progression free survival (PFS) as defined as the time from randomization until the date of assessment of progression (as assessed by BICR based on RECIST v1.1) or death by any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Overall response rate (ORR) defined as the proportion of subjects with ORR (CR and PR) by BICR based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Duration of response defined by the time from CR or PR (by BICR based on RECIST v1.1) until the earlier of the first documentation of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Change from baseline in quality of life as measured by GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Change from baseline in quality of life as measured by Patient-reported outcomes measurement information system (PROMIS) Physical Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Change from baseline in quality of life as measured by EuroQol 5-dimensional questionnaire(EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Change from baseline in pain assessment using brief pain inventory (BPI) short form</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Desmoid</condition>
  <condition>Desmoid Tumor</condition>
  <arm_group>
    <arm_group_label>Part A Main Study 1.2 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL102 1.2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Main Study 2 mg Intermittent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL102 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Main Study 4 mg Intermittent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL102 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B AL102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL102, recommended dose regimen from Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match recommended dose regimen from Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL102</intervention_name>
    <description>AL102 is an inhibitor of gamma secretase-mediated Notch signaling.</description>
    <arm_group_label>Part A Main Study 1.2 mg daily</arm_group_label>
    <arm_group_label>Part A Main Study 2 mg Intermittent</arm_group_label>
    <arm_group_label>Part A Main Study 4 mg Intermittent</arm_group_label>
    <arm_group_label>Part B AL102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match AL102</description>
    <arm_group_label>Part B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Part A:&#xD;
&#xD;
          1. At least 18 years of age (inclusive) at the time of signing the ICF.&#xD;
&#xD;
          2. Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist&#xD;
             (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1&#xD;
             within 12 months of the screening visit scan.&#xD;
&#xD;
          3. At least 1 measurable lesion amenable to volume measurements by MRI at screening (Part&#xD;
             A only)&#xD;
&#xD;
          4. One of the following:&#xD;
&#xD;
               -  Treatment naïve subjects whose disease is not amenable to surgery without the&#xD;
                  risk of significant morbidity; OR&#xD;
&#xD;
               -  Recurrent/refractory disease following at least one line of therapy (including&#xD;
                  surgery, radiation, or systemic therapy).&#xD;
&#xD;
          5. A desmoid tumor in which continued progressive disease will not result in immediate&#xD;
             significant risk to the subject.&#xD;
&#xD;
          6. Agrees to provide formalin-fixed paraffin embedded archival or fresh tumor tissue for&#xD;
             re-confirmation of disease.&#xD;
&#xD;
          7. Must be able to swallow whole capsules with no GI condition affecting absorption;&#xD;
             nasogastric or G-tube administration is not allowed.&#xD;
&#xD;
        Exclusion Criteria Part A:&#xD;
&#xD;
          1. Diagnosed with a malignancy in the past 2 years.&#xD;
&#xD;
          2. Current or recent (within 2 months of IP administration) GI disease or disorders that&#xD;
             increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.&#xD;
&#xD;
          3. Evidence of uncontrolled, active infection, requiring systemic anti-bacterial,&#xD;
             anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known&#xD;
             active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xD;
             at Screening.&#xD;
&#xD;
          4. Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina&#xD;
             pectoris, or has New York Heart Association (NYHA) Class III or IV heart failure, ,&#xD;
             symptomatic ventricular arrhythmias, sustained ventricular tachycardia, Torsade's de&#xD;
             Pointes (TdP), the long QT syndrome, pacemaker dependence, or electrocardiographic&#xD;
             evidence of acute ischemia.&#xD;
&#xD;
          5. Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary&#xD;
             function or uncontrolled diabetes) or any important medical illness or abnormal&#xD;
             laboratory finding that would, in the investigator's judgment, increase the risk to&#xD;
             the subject associated with his or her participation in the study.&#xD;
&#xD;
          6. Pregnant or breastfeeding or expecting to conceive children within the projected&#xD;
             duration of the study.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status ≥2&#xD;
&#xD;
          8. Abnormal organ and marrow function at Screening defined as:&#xD;
&#xD;
               1. Neutrophils &lt;1000/mm3,&#xD;
&#xD;
               2. Platelet count &lt;100,000/mm3,&#xD;
&#xD;
               3. Hemoglobin &lt;9 g/dL,&#xD;
&#xD;
               4. Total bilirubin &gt;1.5x upper limit of normal (ULN) (except known Gilbert's&#xD;
                  syndrome),&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt;2.5x ULN,&#xD;
&#xD;
               6. Serum creatinine &gt; ULN and creatinine clearance (CrCl) &lt;60 mL/min (calculation of&#xD;
                  CrCl will be based on acceptable institution standard)&#xD;
&#xD;
               7. Uncontrolled triglyceride ≥Grade 2 elevations per common terminology criteria for&#xD;
                  adverse events (CTCAE) v5.0 (&gt;300 mg/dL or &gt;3.42 mmol/L).&#xD;
&#xD;
          9. ECG Exclusions (Part A only)&#xD;
&#xD;
               1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450&#xD;
                  msec.&#xD;
&#xD;
               2. QRS duration &gt; 110 ms&#xD;
&#xD;
               3. PR interval &gt; 240 ms&#xD;
&#xD;
               4. Marked ST-T wave abnormalities which would make it difficult to measure the QT&#xD;
                  interval&#xD;
&#xD;
         10. Any treatments for desmoid tumors within 4 weeks prior to first dose of&#xD;
             investigational therapy; subject must have recovered from therapy related toxicity to&#xD;
             &lt; CTCAE Grade 2 or clinical baseline. Therapy includes:&#xD;
&#xD;
               1. Locoregional tumor directed therapies such as major surgery, radiation,&#xD;
                  radiofrequency ablation, or cryosurgery&#xD;
&#xD;
               2. Systemic therapy including chemotherapy, biologic (anti-neoplastic agent,&#xD;
                  antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or&#xD;
                  investigational therapy&#xD;
&#xD;
         11. Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP;&#xD;
&#xD;
        Inclusion Criteria Part B&#xD;
&#xD;
          1. ≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.&#xD;
&#xD;
          2. Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined&#xD;
             according to RECIST v1.1.&#xD;
&#xD;
          3. Subject and/or legally authorized representative (i.e. parent/guardian) must be&#xD;
             capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF.&#xD;
&#xD;
          4. Minor subjects must be capable of giving written assent as appropriate per the&#xD;
             applicable age (per local regulatory requirements).&#xD;
&#xD;
        For all other inclusion criteria refer to Part A inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria Part B The subjects must be excluded from participating in the study if&#xD;
        they meet any of the exclusion criteria for Part A, except where otherwise noted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jason Kaplan, MD</last_name>
    <phone>+1-857-444-0553</phone>
    <email>clinicaltrials@ayalapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johnathan Yoval, MD</last_name>
    <email>clinicaltrials@ayalapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik, MD</last_name>
      <phone>626-218-9200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sant Chawla, MD</last_name>
      <phone>310-552-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nam Bui, MD</last_name>
      <phone>713-412-8721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Brockstein, MD</last_name>
      <phone>847-570-2112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Chugh, MD</last_name>
      <phone>734-936-0452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jefferson City Medical Group</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shadi Haddadin, MD</last_name>
      <phone>573-556-7718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Van Tine, MD</last_name>
      <phone>314-273-4721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrinal Gounder, MD</last_name>
      <phone>646-888-4167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ryan, MD</last_name>
      <phone>503-494-8487</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravin Ratan, MD</last_name>
      <phone>713-745-0258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Andelkovic, MD</last_name>
      <phone>+61731761996</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimit Singhal, MD</last_name>
      <phone>+61882922220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Lewin, MD</last_name>
      <phone>+61385597459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital - Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aviad Zick, MD</last_name>
      <phone>+97226779025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivan Shamai, MD</last_name>
      <phone>+97236972063</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lee, MBChB</last_name>
      <phone>+441614468383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Jones, MBBS</last_name>
      <phone>+44 207 352 8171</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RINGSIDE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

